• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Endocrinology

Sodium-glucose cotransporter 2 inhibitors may reduce incidence of respiratory events in Type 2 diabetics

byMichael WongandAlex Chan
February 16, 2023
in Endocrinology, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this retrospective cohort study, patients with Type 2 Diabetes (T2D) using sodium-glucose cotransporter 2 inhibitors (SGLT2is) were found to have a lower incidence of adverse respiratory events than patients using dipeptidyl peptidase-4 inhibitors (DPP4is).

Evidence Rating Level: 2 (Good)

Type 2 Diabetes (T2D) shares a similar pathophysiological background with respiratory disease. Specifically, glucose levels of the airway surface liquid (ASL) influence respiratory dysfunction; low glucose levels in the ASL help prevent pulmonary infections and the exacerbation of respiratory diseases. Antidiabetic drugs reduce glucose levels, and accumulating evidence suggests that sodium-glucose cotransporter 2 inhibitors (SGLT2is) may offer greater benefit with respect to respiratory outcomes. SGLT2is have been found to reduce the risk of respiratory disorders, pneumonia, and respiratory failure versus dipeptidyl peptidase-4 inhibitors (DPP4is). This retrospective cohort study aimed to determine whether the use of SGLT2is is associated with the risk of adverse respiratory events among patients with T2D compared to DPP4is. Data was collected using the Health Insurance Review and Assessment Service (HIRA) database of South Korea. Patients who were newly prescribed an SGLT2i or DPP4i between January 2016 and December 2020 were identified and included in the study. The primary outcome studied was respiratory events, defined as a composite endpoint including acute pulmonary edema, ARDS, pneumonia, and respiratory failure. In total, after propensity score matching, 205,534 patients were included in each treatment group. With respect to the primary outcome, SGLT2i users displayed a lower incidence of adverse respiratory events when compared to DPP4i users (incidence rate 4.54 versus 7.54 events per 1000 person-years; rate difference: − 3.00, 95% CI − 3.44 to − 2.55). SGLT2i users had lower risks of the composite respiratory endpoint (HR 0.60, 95% CI 0.55 to 0.64), as well as acute pulmonary edema, pneumonia, and respiratory failure. The same trends persisted even after subgroup and stratified analyses, in each age, sex, history of asthma, history of COPD, history of CVD, history of CKD, and history of baseline insulin use subgroup. Overall, the findings from this study suggest that among patients with T2D, SGLT2i users had a 40% lower risk of adverse respiratory events than DPP4i users. A major limitation of this study is the homogenous patient population, as the study was completed in South Korea, which may affect the generalizability of the data. However, this study is an important addition to the growing body of evidence surrounding T2D and respiratory events and will guide further research.

Click to read the study in BMC Medicine

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure

Mazdutide significantly reduces weight in adults with overweight or obesity

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

Tags: diabetesendocrinologyrespirologySGLT2i
Previous Post

Left atrial strain and left atrial strain rate independently associated with risk of ischemic stroke in older adults

Next Post

Youth depression and anxiety rates increased during the COVID-19 pandemic

RelatedReports

Cardiology

SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure

July 11, 2025
Increasing maternal BMI linked to higher risk of cerebral palsy
Cardiology

Mazdutide significantly reduces weight in adults with overweight or obesity

July 11, 2025
Chronic Disease

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

July 7, 2025
#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes
StudyGraphics

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

July 7, 2025
Next Post

Youth depression and anxiety rates increased during the COVID-19 pandemic

Palliative chemotherapy associated with more ICU treatment at end-of-life

Pegylated interferon lambda reduces the risk of COVID-19-related hospitalization

#VisualAbstract: Addition of argatroban to intravenous alteplase did not improve neurologic outcomes in patients with acute ischemic stroke

#VisualAbstract: Addition of argatroban to intravenous alteplase did not improve neurologic outcomes in patients with acute ischemic stroke

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.